NDAINJECTIONINJECTABLEPriority Review
Approved
Dec 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 14h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ETHYOL (amifostine) is an injectable cytoprotective agent approved in 1995 for reducing toxicity associated with chemotherapy and radiation therapy. It functions as a free radical scavenger and antioxidant that protects normal tissues from damage while allowing chemotherapy to remain effective against cancer cells. The drug is administered intravenously prior to cancer treatment.
LOE Approaching
As LOE approaches with moderate competitive pressure (30%), commercial teams should anticipate contraction in headcount and shift focus toward defensive tactics and cost management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer
Started Oct 2006
4 enrolled
Colorectal Cancer
Randomized Amifostine For SCCHN
Started May 2003
58 enrolled
Chemotherapeutic Agent ToxicityHead and Neck CancerMucositis+2 more
Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome
Started Aug 1997
36 enrolled
Myelodysplastic Syndromes
Career Relevance
Working on ETHYOL offers limited career growth opportunities given the LOE-approaching lifecycle stage and zero linked job openings. This product is best suited for early-career professionals gaining oncology expertise or those seeking a stable, lower-intensity role before transitioning to growth-stage brands.
Worked on ETHYOL at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.